Table 2.
ADCs investigated in clinical trials for pancreatic cancer
| Trial Number | Phase | ADC name | Target | Linker | Payload | Status |
|---|---|---|---|---|---|---|
| ADC Monotherapy | ||||||
| NCT05043987 | Phase I | CPO102 | Claudin 18.2 | Cleavable | MMAE (auristatin) | Not yet recruiting |
| NCT05525286 | Phase I/II | SOT102 | Claudin 18.2 | Non-cleavable | Anthracycline PNU159682 | Recruiting |
| NCT05156866 | Phase I | TORL-2-307-ADC | Undisclosed | Undisclosed | Undisclosed | Recruiting |
| NCT05498597 | Phase I | AMT-151 | Folate Receptor alpha | Undisclosed | Undisclosed | Recruiting |
| NCT04659603 | Phase II | Tusamitamab Ravtansine | CEACAM5 | Cleavable | DM4 (maytansinoid) | Recruiting |
| NCT03602079 | Phase I/II | A166 | HER2 | Cleavable | Duo-5 (anti-microtubule agent) | Active, not recruiting |
| NCT01631552 | Phase I/II | Sacituzumab Govitecan-hziy | Trop-2 | Cleavable | SN-38 (topoisomerase I inhibitor) | Completed |
| NCT01166490 | Phase I | ASG-5ME | SLC44A4 | Cleavable | MMAE (auristatin) | Completed |
| NCT03023722 | Phase II | Anetumab Ravtansine | Mesothelin | Cleavable | DM4 (maytansinoid) | Completed |
| NCT02999672 | Phase II | Trastuzumab Emtansine | HER2 | Non-cleavable | DM1 (maytansinoid) | Completed |
| NCT01577758 | Phase I | TAK-264 (MLN0264) | GCC | Cleavable | MMAE (auristatin) | Completed |
| NCT02202785 | Phase II |
TAK-264 (MLN0264) |
GCC | Cleavable | MMAE (auristatin) | Terminated |
| NCT03449030 | Phase I | TAK-164 | GCC | Cleavable | DGN549 (DNA alkylating agent) | Terminated |
| NCT02908451 | Phase I | AbGn-107 | AG7 antigen | Proprietary linker | DM4 (maytansinoid) | Terminated |
| ADC in combination with oral PARP inhibitor AZD5305 | ||||||
| NCT04644068 | Phase I/II |
Trastuzumab Deruxtecan Datopotamab Deruxtecan |
HER2 Trop2 |
Cleavable | Deruxtecan (topoisomerase I inhibitor) | Recruiting |
| ADC in combination with checkpoint inhibition | ||||||
| NCT05293496 | Phase I | MGC018 | B7-H3 | Cleavable | Duocarmycin analog | Recruiting |
| NCT04925284 | Phase I | XB002 | Tissue factor | Proprietary linker | ZymeLink Auristatin | Recruiting |
| NCT03816358 | Phase I | Anetumab Ravtansine | Mesothelin | Cleavable | DM4 (maytansinoid) | Active, not recruiting |
ADC: antibody drug conjugate; B7-H3: B7-homolog 3; CEACAM5: carcinoembryonic antigen-related cell adhesion molecule 5; GCC: Guanylyl Cyclase C; HER2: human epidermal growth factor receptor 2; MMAE: monomethyl auristatin E